Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Intern Med J
; 45(3): 335-43, 2015 Mar.
Article
in En
| MEDLINE
| ID: mdl-25735577
ABSTRACT
Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs (IMiD), proteasome inhibitors and with enhancement in safety of high-dose therapy and autologous stem cell transplant (HDT + ASCT). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant-ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT, including pretreatment considerations, and induction, maintenance and supportive care therapies.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Advisory Committees
/
Stem Cell Transplantation
/
Foundations
/
Multiple Myeloma
Type of study:
Diagnostic_studies
/
Guideline
Limits:
Humans
Country/Region as subject:
Oceania
Language:
En
Journal:
Intern Med J
Year:
2015
Document type:
Article